Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233103
Status:
COMPLETED
Last Update Posted:
2015-11-13
First Post:
2005-10-03
Brief Title:
Treatment of Post-Traumatic Brain Injury TBI Depression
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
Treatment of Post-TBI Depression
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized clinical trial of sertraline vs placebo for post-TBI depression
Detailed Description:
Purpose The purpose of this study is to document the efficacy of sertraline Zoloft in the treatment of depression major depressive disorder after TBI including the impact on quality of life Researchers will also explore the effects of sertraline on anxiety disorders which often accompany post-TBI depression
Background Major depression is experienced by many more people after TBI than prior to injury and more often than in people without a brain injury Many studies have also shown that this higher than normal incidence looms for many years post TBI Major depression is associated with a variety of negative outcomes including poorer functioning in basic activities reduced employment elevated divorce rate reduced social and recreational activity and increased sexual dysfunction
Need for Research Of the current drug treatments for major depression sertraline and similar drugs known as selective serotonin reuptake inhibitors or selective serotonin reuptake inhibitor SSRIs have few side effects in people who have experienced a brain injury and have been shown to be effective in people with no known brain injury However information on the impact of SSRIs on post-TBI depression based on randomized double-blind studies is unavailable
Current Research Activity Approximately 50 men and women volunteers who are post TBI and currently diagnosed with major depressive disorder are being randomly assigned to a 12-week period of taking Zoloft or a placebo Over the period of study participants will have the severity of their depressive symptoms assessed as well as their symptoms of anxiety a simple measure of the volunteers perceived quality of life will be implemented prior to the study and at its termination It is hypothesized that sertraline will reduce the symptoms of depression and anxiety and will increase the persons perceived quality of life to a significantly greater extent than will the placebo
Background Major depression is experienced by many more people after TBI than prior to injury and more often than in people without a brain injury Many studies have also shown that this higher than normal incidence looms for many years post TBI Major depression is associated with a variety of negative outcomes including poorer functioning in basic activities reduced employment elevated divorce rate reduced social and recreational activity and increased sexual dysfunction
Need for Research Of the current drug treatments for major depression sertraline and similar drugs known as selective serotonin reuptake inhibitors or selective serotonin reuptake inhibitor SSRIs have few side effects in people who have experienced a brain injury and have been shown to be effective in people with no known brain injury However information on the impact of SSRIs on post-TBI depression based on randomized double-blind studies is unavailable
Current Research Activity Approximately 50 men and women volunteers who are post TBI and currently diagnosed with major depressive disorder are being randomly assigned to a 12-week period of taking Zoloft or a placebo Over the period of study participants will have the severity of their depressive symptoms assessed as well as their symptoms of anxiety a simple measure of the volunteers perceived quality of life will be implemented prior to the study and at its termination It is hypothesized that sertraline will reduce the symptoms of depression and anxiety and will increase the persons perceived quality of life to a significantly greater extent than will the placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H133A020501 | None | None | None |